Harrow Health/$HROW
13:30
15:10
16:45
18:25
20:00
1D1W1MYTD1Y5YMAX
About Harrow Health
Harrow Inc is an eyecare pharmaceutical company engaged in the discovery, development, and commercialization of ophthalmic pharmaceutical products for the U.S. market. The company helps U.S. eyecare professionals preserve the gift of sight by making its comprehensive portfolio of prescription and non-prescription pharmaceutical products accessible and affordable to millions of Americans. Its operating segments are The Branded segment includes activities of the Company's FDA-approved ophthalmology pharmaceutical products, including the out-licensing of rights to certain of branded products; and The ImprimisRx segment represents activities in the Company's ophthalmology-focused pharmaceutical compounding business.
Ticker
$HROW
Sector
Primary listing
Employees
382
Headquarters
Website
Harrow Health Metrics
BasicAdvanced
$1.6B
-
-$0.29
0.33
-
Price and volume
Market cap
$1.6B
Beta
0.33
52-week high
$56.01
52-week low
$20.85
Average daily volume
635K
Financial strength
Current ratio
0.622
Quick ratio
0.542
Long term debt to equity
95.032
Total debt to equity
95.032
Interest coverage (TTM)
0.59%
Profitability
EBITDA (TTM)
30.825
Gross margin (TTM)
74.56%
Net profit margin (TTM)
-4.49%
Operating margin (TTM)
6.44%
Effective tax rate (TTM)
4.61%
Revenue per employee (TTM)
$600,000
Management effectiveness
Return on assets (TTM)
2.81%
Return on equity (TTM)
-19.03%
Valuation
Price to revenue (TTM)
6.787
Price to book
31.94
Price to tangible book (TTM)
-12.22
Price to free cash flow (TTM)
-44.626
Free cash flow yield (TTM)
-2.24%
Free cash flow per share (TTM)
-0.961
Growth
Revenue change (TTM)
47.69%
Earnings per share change (TTM)
-70.08%
3-year revenue growth (CAGR)
39.23%
10-year revenue growth (CAGR)
47.98%
3-year earnings per share growth (CAGR)
-31.76%
10-year earnings per share growth (CAGR)
-14.01%
What the Analysts think about Harrow Health
Analyst ratings (Buy, Hold, Sell) for Harrow Health stock.
Bulls say / Bears say
Harrow reported Q2 2025 revenue of $63.7 million, up 30% year-on-year, and adjusted EBITDA of $17.0 million, demonstrating strong leverage and improved profitability (GlobeNewswire)
VEVYE captured almost 3% market share in Q2, with sequential prescription growth of 66% and around 50,000 new prescriptions, indicating robust commercial uptake (GlobeNewswire)
In June 2025, Harrow obtained exclusive U.S. rights to BYQLOVI™, the first FDA-approved ophthalmic steroid in its class in 15 years, entering the $500 million-plus post-surgical inflammation market (Business Wire)
Harrow’s Q2 revenue of $63.7 million fell short of the $66 million consensus estimate, pointing to potential pricing or demand headwinds despite strong annual growth (Investing.com)
VEVYE's sequential revenue dropped to $18.6 million in Q2 from $21.5 million in Q1, as the VEVYE Access for All program pressured average selling prices, raising concerns over margin compression (Investing.com)
With H1 2025 revenue at $111.6 million versus full-year guidance exceeding $280 million, Harrow needs to generate roughly $169 million in H2—over 60% of the annual target in six months—posing execution challenges (Investing.com)
Data summarised monthly by Lightyear AI. Last updated on 30 Aug 2025.
Harrow Health Financial Performance
Revenues and expenses
Harrow Health Earnings Performance
Company profitability
Harrow Health News
AllArticlesVideos
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.
Capital at risk
Upcoming events
No upcoming events
FAQs
What’s the current market cap for Harrow Health stock?
Harrow Health (HROW) has a market cap of $1.6B as of September 18, 2025.
What is the P/E ratio for Harrow Health stock?
The price to earnings (P/E) ratio for Harrow Health (HROW) stock is 0 as of September 18, 2025.
Does Harrow Health stock pay dividends?
No, Harrow Health (HROW) stock does not pay dividends to its shareholders as of September 18, 2025.
When is the next Harrow Health dividend payment date?
Harrow Health (HROW) stock does not pay dividends to its shareholders.
What is the beta indicator for Harrow Health?
Harrow Health (HROW) has a beta rating of 0.33. This means that it is less volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 0.5 would mean it moves half as much as the market.